Dapagliflozin Effects in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The DAPA-STEMI Randomized Clinical Trial
This study showed that dapagliflozin could significantly improve LVEF among patients whose LVEF dropped to ≤40% post-STEMI. However, further studies are required to confirm the study findings.
Authors
- Elnaz Javanshir (ORCID: https://orcid.org/0000-0003-4244-7735)
- Sima Ghaffari (ORCID: https://orcid.org/0000-0002-8189-4397)
- Hoda Afsharirad
- Elnaz Khani
- Shirin Allord
Institutions
- Tabriz University of Medical Sciences (IR)
Publication Details
- Journal
- American Journal of Therapeutics
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1097/mjt.0000000000002077
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00